# Q Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/q-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Salt Lake City, US
- Website: www.qthera.com
- Total disclosed funding: $15M
- Latest round: Series B (Feb 15, 2008)
- Investors on record: 7

## About

Q Therapeutics Inc. is dedicated to the development of innovative human-cell-based therapies for debilitating diseases affecting the central nervous system, focusing on their proprietary Q-Cells® technology.Q Therapeutics Inc. specializes in creating human-cell-based therapies, with its headquarters located in Salt Lake City, US. Founded by M. Mahendra, the company has undergone significant changes in its business strategy and has successfully advanced its product pipeline. The company has raised a total of USD 15.00 mn through its latest funding round, Series B, led by Signal Peak Ventures on February 15, 2008, with participation from various investors including EPIC Ventures and Invitrogen Corporation. Q Therapeutics has one recorded deal since its inception.Q Therapeutics focuses on developing innovative human-cell-based therapies aimed at treating currently incurable diseases of the central nervous system (CNS), primarily through its flagship product, Q-Cells®. These human glial progenitor cells are designed to support, repair, and maintain neuronal function in the brain and spinal cord. The technology has shown the ability to replicate, migrate, and differentiate into specialized glial cells at sites of CNS injury or disease. The company has received FDA allowance for an Investigational New Drug (IND) application to advance to a Phase 1/2a clinical trial for Q-Cells® targeting patients with Transverse Myelitis, affecting approximately 40,000 individuals in the United States.The specific revenue structure of Q Therapeutics is not publicly disclosed. The company operates within a typical biopharmaceutical framework, likely involving transactions with healthcare institutions, hospitals, and clinical research organizations. Revenue generation may stem from sales of Q-Cells® as an off-the-shelf pharmaceutical product, prepared for therapeutic use upon regulatory approval. The company’s focus on CNS diseases suggests revenue will heavily depend on partnerships with healthcare providers for clinical trials and future commercial distribution, contingent upon successful regulatory approvals. The pricing structure for Q-Cells® is not specified but is expected to align with standard practices in the biotechnology sector.Q Therapeutics aims to leverage the recent USD 15.00 mn funding from its Series B round to support the development of its Q-Cells® product line and expand clinical trials. The company plans to enhance its offerings and potentially explore new markets, particularly in North America, while considering future expansion into other regions as product development progresses. The focus will include launching new products to address CNS diseases and establishing partnerships with healthcare providers for further clinical trials and distribution opportunities.

## Funding rounds

- Series B, Feb 15, 2008, $15M — Schroders Capital, EPIC Ventures, Toucan Capital, Signal Peak Ventures, Invitrogen Corporation, Life Science Angels, Inc., University of Utah Research Foundation

## Investors

- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series B
- EPIC Ventures (https://capitalatlas.ai/funds/epic-ventures) — Series B
- Toucan Capital (https://capitalatlas.ai/funds/toucan-capital) — Series B
- Signal Peak Ventures (https://capitalatlas.ai/funds/signal-peak-ventures) — Series B
- Invitrogen Corporation — Series B
- Life Science Angels, Inc. — Series B
- University of Utah Research Foundation — Series B